Funded by private investors and governments, cancer tests of blood and urine are coming to market.
How much does it cost to bring to market a diagnostic test that’s able to measure cancer without a tissue biopsy?
In the case of Trovagene, almost $100 million.
That’s the cumulative loss, or expense including salaries, R&D, and office space, the money-losing San Diego biotechnology outfit has run up since 1999, when it set out to test for cancer from a cup of urine. Just like recently developed cancer blood tests, the diagnostic the company started offering in May searches for telltale scraps of tumor DNA released by dying cancer cells. The amount of tumor DNA that ends up in urine is a readout, the company says, of whether a tumor has been destroyed or is still growing.
Wall Street analysts expect demand for liquid biopsies to rocket toward $20 billion a year within five years, from about $100 million today.
The idea of such liquid biopsies has leapt to prominence in just the last year. Cancer researchers now expect that the tests will offer a noninvasive way to monitor cancer, find the genetic mutations driving a tumor, or even diagnose it early, before symptoms start. It’s an innovation so big that Wall Street analysts at JP Morgan expect demand for liquid biopsies to rocket toward $20 billion a year within five years, from about $100 million today.
The first DNA blood test for cancer in the United States was commercialized in 2014 by Guardant Health, a venture-backed California company, and tests to spot cancer DNA in blood, urine, or spinal fluid are now in development by a growing number of companies but remain a risky bet for investors.
One pioneering researcher, Dennis Lo, is now tracking more than 20,000 people in Hong Kong to see whether blood screening can catch liver cancer early. Some of his early and ongoing work was paid for by a $1 million grant from the Kadoorie Charitable Foundation, the charity of Hong Kong billionaire Michael Kadoorie, and he later won a $4.25 million award from the Hong Kong government. “It took us about 10 years to convince people to fund us,” he says. Lo says he recently cofounded a company called Cirina to develop blood tests, and he expects initial financing of $12 million from investors.
Investors in the new tests could be disappointed, because while developing a new diagnostic can cost as much as creating a new drug, it’s notoriously hard to make any money off diagnostic tests.
The Latest on: Liquid Biopsy
via Google News
The Latest on: Liquid Biopsy
- Why Illumina Was Up 17% in Juneon July 8, 2021 at 1:44 pm
Shares of Illumina (NASDAQ:ILMN) gained 17% last month, according to S&P Global Market Intelligence. The stock climbed steadily throughout the month after its Grail spinoff presented impressive data ...
- Liquid Biopsy for Cancer Diagnostics Competitive Landscape and Pipeline Analysis Report 2021 - ResearchAndMarkets.comon July 8, 2021 at 1:00 am
The "Liquid Biopsy for Cancer Diagnostics - Competitive Landscape and Pipeline Analysis, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.This "Liquid Biopsy for Cancer ...
- Angle PLC Announces Director/PDMR Shareholdingon July 7, 2021 at 11:16 am
ANGLE plc Director/PDMR Shareholding Exercise of Options and Total Voting Rights. GUILDFORD, SURREY / ACCESSWIRE / July 7, 2021 / ANGLE plc (‘ANGLE’ or the ‘Company’) (AIM ...
- Alternating Nucleix’s Bladder EpiCheck® With Standard Surveillance Can Reduce Burden on Patients and Healthcare Systemson July 7, 2021 at 12:00 am
Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, today announced the publication of an analysis highlighting that Bladder EpiCheck® can reduce both ...
- Liquid Biopsy Market 2021 to 2024 Growth Factors, Market Characteristics, Manufactures, Size, Share, Opportunities By Type Analysis and Forecaston July 6, 2021 at 7:44 pm
The MarketWatch News Department was not involved in the creation of this content. Jul 07, 2021 (The Expresswire) -- Global "Liquid Biopsy Market" report 2021 present key analysis on the market status ...
- Guardant Health, Inc.: Guardant's Growth Set to Accelerate Along With Expanding Liquid Biopsy Test Portfolioon July 6, 2021 at 5:00 pm
Find the latest Guardant Health, Inc. (GH) stock forecast based on top analyst's estimates, plus more investing and trading data from Yahoo Finance ...
- Liquid Biopsy Has Potential to Advance Precision Medicine in Melanomaon July 2, 2021 at 7:15 am
Years of research has shown that in cancers like melanoma, liquid biopsy enables the detection of biomarkers, such as circulating tumor cells, circulating tumor DNA, and exomes.
- Global Liquid Biopsy Market Size to Reach $6.80 billion by 2028, At CAGR of 20.9%: Allied Market Researchon July 1, 2021 at 3:36 am
Portland, OR, July 01, 2021 (GLOBE NEWSWIRE) -- According to the report published by Allied Market Research, the global Liquid Biopsy Market garnered $1.20 billion in 2020, and is estimated to reach ...
- How a Cutting-Edge Liquid Biopsy for Cancer Was Created at MSKon June 30, 2021 at 9:00 pm
MSK-ACCESS, a blood test that can detect mutations in 129 genes related to cancer, has already helped guide the treatment of more than 2,800 patients at MSK.
- So Much More than Just Another Liquid Biopsy Companyon June 27, 2021 at 5:09 pm
Adela has raised $60 million in a series A round. The company’s technology looks at the DNA methylome, which is a rich source of information about human disease.
via Bing News